How Big Pharma Weaponized the FDA to Kill Your Access to Personalized Medicine скачать в хорошем качестве

How Big Pharma Weaponized the FDA to Kill Your Access to Personalized Medicine

Compounding pharmacies are under attack — and millions of patients could lose access to affordable medications because of it. In this deep dive, Dr. Alex Tatem, board-certified urologist and men’s health specialist, breaks down the growing conflict between Big Pharma, the FDA, and compounding pharmacies that provide personalized medications like TRT, HCG, semaglutide, tirzepatide, and fertility treatments. Pharmaceutical companies such as Novo Nordisk and Eli Lilly are generating tens of billions from GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. Meanwhile, compounding pharmacies have been producing lower-cost versions during nationwide drug shortages — sometimes for $100–$300 per month instead of $1,000+. Now lawsuits, legislation, and regulatory pressure threaten to shut that system down entirely. This video explains: • What compounding pharmacies are (503A vs 503B) • Why GLP-1 drugs like semaglutide and tirzepatide are at the center of the fight • The lawsuits filed by Novo Nordisk and Eli Lilly • The FDA’s biologics reclassification that banned compounded HCG • How drug shortages allowed compounding of semaglutide and tirzepatide • The proposed SAFE Drugs Act (H.R. 6509) • Indiana Senate Bill 282 and state-level restrictions • The economics behind the $100B GLP-1 drug market • Why personalized medicine and compounding pharmacies exist in the first place • The potential impact on TRT, fertility treatments, and weight-loss medications Dr. Tatem also outlines a policy solution that could expand patient access while maintaining safety oversight. If you care about drug pricing, medical freedom, fertility access, TRT, GLP-1 medications, or personalized medicine, this is a conversation that affects you. 👍 Like the video to help this reach more patients 💬 Comment your experience with compounded medications 📤 Share this video so policymakers and patients can hear the discussion 🔔 Subscribe for more science-based analysis on men’s health, pharmaceuticals, and medical policy Timecodes: 00:00 Intro — Big Pharma vs Compounding Pharmacies 01:22 What Compounding Pharmacies Actually Do 03:12 The 2020 Biologics Reclassification (HCG Ban) 04:24 FDA Pressure on Compounding Pharmacies 05:30 The GLP-1 Drug Explosion (Ozempic, Wegovy, Mounjaro) 06:37 Drug Shortages & Why Compounding Was Allowed 07:03 Big Pharma Lawsuits Against Compounders 07:55 Novo Nordisk vs Hims & Hers Lawsuit 09:28 The $49 Semaglutide Timeline 10:23 Oral Semaglutide Isn’t New (Rybelsus vs Wegovy) 11:50 SNAC Explained — How Oral GLP-1 Works 12:54 Novo Nordisk Contradiction on Compounding 13:37 Is This About Safety… or Profit? 14:01 State Laws Targeting Compounding Pharmacies 15:11 The SAFE Drugs Act (H.R. 6509) 16:01 Why This Fight Is Personal for Patients 17:26 The FDA’s Mission vs What’s Happening 18:37 The Mar-a-Lago Dinner Timeline 19:40 TrumpRx Drug Pricing Deal 20:57 Why Compounding Is Still Cheaper 21:21 My Plan to Fix This 22:46 Step 1 — Let Compounders Compete 23:09 Step 2 — 503A + 503B Safety Model 23:35 Step 3 — Add Compounded Drugs to TrumpRx 24:00 Step 4 — Reverse the Biologics Ban 24:24 Step 5 — National Security & Drug Supply 26:50 Message to Secretary Kennedy 27:15 Message to FDA Commissioner Makary 28:24 Message to Admiral Christine 29:09 Message to Dr. Brenner 30:03 Message to Deputy Secretary O’Neill 30:27 Trump Administration Fertility Promises 31:18 A Generational Opportunity for Healthcare 32:34 My Position on Pharma Innovation 33:16 Will Anyone in Power See This? 33:56 Why Speaking Up Matters 34:33 What You Can Do (Call Your Representatives)